EQRx adds ar­mor to its dis­count check­point in­hibitor sub­mis­sion, nail­ing sur­vival mark in key study

The rules say you can’t dis­rupt any mar­ket un­less you are, in fact, a part of that mar­ket — and self-styled drug pric­ing dis­rup­tor EQRx is one step clos­er to do­ing just that.

A com­bi­na­tion of EQRx and CStone’s PD-(L)1 drug sug­e­mal­imab and chemother­a­py sig­nif­i­cant­ly pro­longed pa­tients’ lives over place­bo in pa­tients with new­ly di­ag­nosed stage IV non-small cell lung can­cer, ac­cord­ing to up­dat­ed da­ta from the Phase III GEM­STONE-302 study un­veiled Tues­day evening.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER